Vimseltinib Patent Expiration

Vimseltinib was first introduced by Deciphera Pharmaceuticals Llc in its drug Romvimza on Feb 14, 2025.

Vimseltinib Patents

Given below is the list of patents protecting Vimseltinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Romvimza	US11103507	Methods of treating disorders using CSF1R inhibitors	Feb 03, 2040	Deciphera Pharms
Romvimza	US11679110	Methods of treating disorders using CSF1R inhibitors	Feb 03, 2040	Deciphera Pharms
Romvimza	US9181223	2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities	Mar 14, 2034	Deciphera Pharms

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List